Comparative effectiveness of nivolumab versus regorafenib for hepatocellular carcinoma patients who experienced sorafenib failure

被引：0
|
作者：
Bin Lee, Yun [1 ]
Lee, Cheol-Hyung [1 ]
Kim, Minseok Albert [1 ]
Jang, Heejoon [1 ]
Oh, Hyunwoo [1 ]
Kim, Sun Woong [1 ]
Cho, Eun Ju [1 ]
Lee, Kyung-Hun [2 ,3 ]
Lee, Jeonghoon [1 ]
Yu, Su Jong [1 ]
Yoon, Jung-Hwan [1 ]
Kim, Tae-You [2 ,3 ]
Kim., Yoon Jun [1 ]
机构：
[1] Seoul Natl Univ Coll Med, Dept Internal Med & Liver Res Inst, Seoul, South Korea
[2] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[3] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea
来源：
JOURNAL OF HEPATOLOGY | 2020年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT519
引用
收藏
页码：S913 / S914
页数：2
相关论文
共 50 条
  • [1] REGORAFENIB VERSUS NIVOLUMAB FOR HEPATOCELLULAR CARCINOMA PATIENTS WHO EXPERIENCED SORAFENIB TREATMENT FAILURE: A PROPENSITY SCORE ANALYSIS
    Lee, Cheol-Hyung
    Lee, Yun Bin
    Kim, Minseok Albert
    Jang, Heejoon
    Kim, Sun Woong
    Cho, Eun Ju
    Lee, Jeong-Hoon
    Yu, Su Jong
    Yoon, Jung-Hwan
    Kim, Yoon Jun
    HEPATOLOGY, 2019, 70 : 212A - 213A
  • [2] Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
    Lee, Cheol-Hyung
    Lee, Yun Bin
    Kim, Minseok Albert
    Jang, Heejoon
    Oh, Hyunwoo
    Kim, Sun Woong
    Cho, Eun Ju
    Lee, Kyung-Hun
    Lee, Jeong-Hoon
    Yu, Su Jong
    Yoon, Jung-Won
    Kim, Tae-You
    Kim, Yoog Jun
    CLINICAL AND MOLECULAR HEPATOLOGY, 2020, 26 (03) : 328 - 339
  • [3] Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
    Kuo, Yuan-Hung
    Yen, Yi-Hao
    Chen, Yen-Yang
    Kee, Kwong-Ming
    Hung, Chao-Hung
    Lu, Sheng-Nan
    Hu, Tsung-Hui
    Chen, Chien-Hung
    Wang, Jing-Houng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [4] Comparative effectiveness of regorafenib and nivolumab as sequential therapies in patients after sorafenib failure for hepatocellular carcinoma patients: A cohort study in Taiwan
    Yeh, Tzuyu
    Chang, Kaicheng
    Chen, Hui-Yu
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 343 - 344
  • [5] Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma
    Choi, Won-Mook
    Choi, Jonggi
    Lee, Danbi
    Shim, Ju Hyun
    Lim, Young-Suk
    Lee, Han Chu
    Chung, Young-Hwa
    Lee, Young-Sang
    Park, Sook Ryun
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Lee, So Jung
    Kim, Kang Mo
    HEPATOLOGY COMMUNICATIONS, 2020, 4 (07) : 1073 - 1086
  • [6] Regorafenib versus nivolumab after sorafenib failure: real-world data in patients with hepatocellular carcinoma
    Choi, Won-Mook
    Choi, Jonggi
    Shim, Ju Hyun
    Lim, Young-Suk
    Lee, Han Chu
    Kim, Kang Mo
    JOURNAL OF HEPATOLOGY, 2020, 73 : S39 - S39
  • [7] Regorafenib compared to nivolumab after sorafenib failure in patients with hepatocellular carcinoma: A systematic review and meta-analysis
    Yang, Shuheng
    Zhou, Yadong
    Zeng, Lei
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 32 (08): : 839 - 845
  • [8] Sorafenib versus nivolumab after lenvatinib treatment failure in patients with advanced hepatocellular carcinoma
    Kim, Yuna
    Lee, Jae Seung
    Lee, Hye Won
    Kim, Beom Kyung
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Goh, Myung Ji
    Kang, Wonseok
    Kim, Seung Up
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2023, 35 (02) : 191 - 197
  • [9] Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis
    Shlomai, Amir
    Leshno, Moshe
    Goldstein, Daniel A.
    PLOS ONE, 2018, 13 (11):
  • [10] Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma
    Lee, Hong Jun
    Lee, Jae Seung
    So, Hyesung
    Yoon, Ja Kyung
    Choi, Jin-Young
    Lee, Hye Won
    Kim, Beom Kyung
    Kim, Seung Up
    Park, Jun Yong
    Ahn, Sang Hoon
    Kim, Do Young
    YONSEI MEDICAL JOURNAL, 2024, 65 (07) : 371 - 379
12345